http://www.genengnews.com/news/bnitem.aspx?name=3415123
<P>By Biowire, July 19, 2006 (genengnews.com) – Geron Corporation announced today the publication of preclinical studies that support the safety and utility of GRNOPC1, Geron’s lead human embryonic stem cell (hESC)-based therapeutic product for the treatment of spinal cord injury. </P> <P>In the studies published in Regenerative Medicine, Dr. Hans Keirstead and his colleagues at the University of California, Irvine, injected GRNOPC1 into the lesion site of rats that received either very mild or moderate spinal cord contusion injuries. GRNOPC1 survived in both the mild and moderate lesion sites, with a broader distribution of transplanted cells and robust remyelination in the more severe injuries, replicating previous studies. </P>